March 19, 2020 / 1:03 PM / 20 days ago

BRIEF-Phathom Pharma Pauses New Patient Randomization In Trials Due To Coronavirus

March 19 (Reuters) - Phathom Pharmaceuticals Inc:

* PHATHOM REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CLINICAL TRIAL STATUS AND BUSINESS UPDATES

* PHATHOM PHARMACEUTICALS INC - TEMPORARILY PAUSING NEW PATIENT RANDOMIZATION IN PHALCON-EE AND PHALCON-HP TRIALS IN VIEW OF COVID-19 PANDEMIC

* PHATHOM PHARMACEUTICALS - DECISION TO TEMPORARILY PAUSE NEW PATIENT RANDOMIZATION IS NOT BASED ON ANY STUDY-RELATED EVENTS

* PHATHOM PHARMACEUTICALS INC - EXPECTS TO REMAIN ON TRACK TO PROVIDE TOP-LINE DATA FOR BOTH PHALCON-EE AND PHALCON-HP CLINICAL TRIALS IN 2021

* PHATHOM PHARMACEUTICALS INC - Q4 NET LOSS FOR 2019 WAS $98.0 MILLION, COMPARED TO $484,000 FOR Q4 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below